Sanofi has completed its acquisition of Blueprint Medicines, enhancing its portfolio with a commercialised therapy and the ...

Key Points - Revenue rose 3.0 % year over year to $10.85 billion, surpassing analyst expectations.- Non-GAAP earnings per ...

Casper claimed that during the quarter, Thermo Fisher advanced its growth strategy, launching a range of high-impact ...

Q2 2025 Management View CEO Marc N. Casper highlighted "excellent operational performance in the quarter, reflecting active management of our company and the strength of our proven growth strategy and ...

Thermo Fisher Scientific's second quarter of 2025 demonstrated a 3% revenue increase to $10.85 billion, slightly surpassing ...

Thermo Fisher Scientific (NYSE:TMO) stock gains as company beats Q2 2025 forecasts with $10.9B revenue, driven by Life ...

Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the second quarter ended June 28, 2025.

Detailed price information for Thermo Fisher Scientific Inc (TMO-N) from The Globe and Mail including charting and trades.

The French pharma will pay $1.15 billion upfront to buy Vicebio and gain access to non-mRNA vaccine candidates against RSV ...

Thermo Fisher Scientific Inc. just made headlines with its hefty $17.6 billion acquisition of PPD, Inc., aiming to bolster ...

Company management said they expect the tariff battle with China to cause weakening of $375 million in adjusted operating income.

In the bustling realm of life sciences, Thermo Fisher Scientific shows formidable resilience and innovation. The company's Q2 2025 earnings reveal a revenue of $10.85 billion, marking a 3% ...